Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-ascending-dose safety, tolerability, and pharmacokinetic study of SCH 900229 in healthy adults
NL-OMON34885Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2009
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised trial in Alzheimer's disease (AD) comparing SCH 900229 with Placebo (2 arms). Started Dec 2009; status: active, not recruiting.
02
Drugs
ambrosia artemisiifolia allergen extract
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON34885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34885.